great times, page-24

Fast forward 12 months and POH is now a very very different beast.

Esra made a point of promising very strong newsflow for the bal of the year. Its safe to bet that some of that will be devoted to new Opioids to join the Pain Portfolio....expect at least one more to join the 2013 Q3/4 trials was my impression from those at the AGM. So POHs strategic ambition ( in terms of making a name for itself) now seems to be to become the Bio equivalent of a Onestop Shop for Pain products-whatever you need POH will formulate it. Its a high value area with patent cliffs and unmet needs by a growing and ageing population demanding safer and more efficaceous pain products without the side effects.

So I am very comforted by POHs 2013 strategies as laid out to shareholders this past week and the fact that POH is now in control of its own destiny. The hard work with Labtech on developing a best in class pain patch is ticked off. The trials ahead are designed by Esra and her team to provide the results they deem necessary to do a Pharma deal and produce the best possible package for the FDA. Esra is taking every precaution to derisk the platform and achieve her near term goal of creating Aust largest Biotech Deal.